GinnaG.(Gastillo)LaportMD

Oncology • South San Francisco, CA

Hematologic Oncology

Vice President, Global Head of NHL/CLL Clinical Development Genentech/Roche

Join to view full profile

Dr. Laport is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Laport's full profile

Already have an account?

Office
Genentech/Roche
One DNA Way
South San Francisco, CA 94080
Phone+1 650-387-7276

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 1994 - 1997
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 1993 - 1994
University of ChicagoResidency, Internal Medicine, 1990 - 1993
McGovern Medical School at UTHealthClass of 1990
Baylor UniversityBA, Psychology, 1982 - 1986

Certifications & Licensure

CA State Medical License 1993 - 2026

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202) Start of enrollment: 2004 Aug 01
Terminated
Phase 2, Phase 3
Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML) Start of enrollment: 2002 May 01
Terminated
Haploid Allogeneic Transplant Using the CliniMACS System Start of enrollment: 2001 Nov 01
Terminated
Phase 2
Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders Start of enrollment: 2001 Dec 01
Completed
Not Applicable
High Dose Chemotherapy and Autologous Transplant for Breast Cancer
Unknown status
Phase 2
CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant Start of enrollment: 1996 Sep 01
Completed
Phase 1, Phase 2
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma Start of enrollment: 2007 Jan 01
Terminated
Phase 2
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma Start of enrollment: 2009 May 01
Completed
Phase 2
Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701) Start of enrollment: 2009 Apr 01
Completed
Phase 2
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells Start of enrollment: 2009 Jun 01
Terminated
Phase 1, Phase 2
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) Start of enrollment: 2010 May 01
Completed
Phase 3
Social Adaptation in Long Term Survivors of Blood and Marrow Transplantation Start of enrollment: 2009 Nov 01
Completed
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders Start of enrollment: 2011 Mar 01
Completed
Phase 2
Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD Start of enrollment: 2013 Jul 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

20 citations
Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.
Matthew J. Frank, Michael S. Khodadoust, Debra K. Czerwinski, Ole Audun Werner Haabeth, Michael P. Chu
The Journal of Experimental Medicine. 2020-09-07
140 citations
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
Lawrence Fong, Andrew Hotson, John D. Powderly, Mario Sznol, Rebecca S. Heist
Cancer Discovery. 2020-01-01
16 citations
Donor-Derived Cytokine-Induced Killer Cell Infusion as Consolidation after Nonmyeloablative Allogeneic Transplantation for Myeloid Neoplasms.
Rupa Narayan, Jonathan Benjamin, Omid Shah, Lu Tian, Keri Tate
Biology of Blood and Marrow Transplantation. 2019-07-01

Lectures

Phase 1/1b multicenter trial of TPST-1120, a peroxisome proliferator-activated receptor alpha (PPARα) antagonist as a single agent (SA) or in combination in patients w...
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
Industry Careers
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
2012 Highlights of ASH in North America (Las Vegas, NV)
American Society of Hematology (ASH), Las Vegas, Nevada - 1/27/2012

Press Mentions

Epkinly (Epcoritamab) Approved as First Bispecific Antibody for Most Common Non-Hodgkin’s LymphomaMay 25th, 2023
Interview About New Follicular Lymphoma Drug Lunsumio with Genentech’s Dr. Ginna LaportFebruary 24th, 2023
Tempest Therapeutics Starts Phase I/Ib Clinical Trial with First-in-Class PPAR Alpha AntagonistMay 16th, 2019
Join now to see all